File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/lt.23901
- Scopus: eid_2-s2.0-84932186609
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Conference Paper: Histological outcome after liver transplantation for chronic hepatitis B using oral antiviral therapy alone without hepatitis B immune globulin
Title | Histological outcome after liver transplantation for chronic hepatitis B using oral antiviral therapy alone without hepatitis B immune globulin |
---|---|
Authors | |
Keywords | Medical sciences Gastroenterology medical sciences Surgery |
Issue Date | 2014 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021 |
Citation | The 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S134, abstract O-97 How to Cite? |
Abstract | AIM: To determine the histological outcome after liver transplantation for patients with chronic hepatitis B (CHB) receiving oral antiviral therapy without hepatitis B immune globulin (HBIG). METHODS: All patients transplanted for CHB-related complications from January 2003 to December 2012 were included. None of the patients received HBIG. All biopsies performed 3 months after transplantation were analyzed. Biopsies were performed on the basis of graft dysfunction. Immunohistochemical study with anti-hepatitis B surface antigen (HBsAg) antibody was performed. RESULTS: A total of 440 CHB patients underwent liver transplantation with a median follow-up of 58 months (range, 0-130). Of these, 139 (31.6%) patients underwent liver biopsy for graft dysfunction, with a total of 258 biopsies performed. The median time to biopsy was 10 months (range, 3-104). Forty-five patients had positive serum HBsAg at the time of biopsy, of which 6 were positive for HBsAg stain. All 6 patients were on lamivudine with known virological rebound due to resistance. In the remaining 39 patients with negative HBsAg stain, 7 patients had grade 1 fibrosis from non-HBV related causes. Forty patients were on entecavir monotherapy, of which 9 patients were positive for serum HBsAg at the time of biopsy and all were negative for HBsAg staining; only 1 had grade 1 fibrosis from non-hepatitis B cause. In the remaining 94 patients who were HBsAg-negative at the time of biopsy, none had histological evidence of recurrence of hepatitis B. CONCLUSION: For patients without virological rebound, positive serum HBsAg was not associated with histological evidence of recurrent hepatitis B infection after liver transplantation. For patients receiving entecavir monotherapy, no histological evidence of recurrent hepatitis B was observed irrespective of the serum HBsAg status. |
Description | Oral Abstract Session - Recurrent Disease/Pathology: O-97 Young Investigator Awards: James Fung This free journal suppl. entitled: The ILTS 20th Annual International Congress |
Persistent Identifier | http://hdl.handle.net/10722/206846 |
ISSN | 2023 Impact Factor: 4.7 2023 SCImago Journal Rankings: 1.700 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Fung, J | - |
dc.contributor.author | Lo, R | - |
dc.contributor.author | Chan, SC | - |
dc.contributor.author | Chok, KSH | - |
dc.contributor.author | Sharr, WW | - |
dc.contributor.author | Dai, WC | - |
dc.contributor.author | Cheung, TT | - |
dc.contributor.author | Chan, ACY | - |
dc.contributor.author | Wong, T | - |
dc.contributor.author | Ng, IOL | - |
dc.contributor.author | Yuen, MF | - |
dc.contributor.author | Lo, CM | - |
dc.date.accessioned | 2014-12-02T10:28:24Z | - |
dc.date.available | 2014-12-02T10:28:24Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | The 2014 Joint International Congress of ILTS, ELITA and LICAGE, London, UK., 4-7 June 2014. In Liver Transplantation, 2014, v. 20 suppl. S1, p. S134, abstract O-97 | - |
dc.identifier.issn | 1527-6465 | - |
dc.identifier.uri | http://hdl.handle.net/10722/206846 | - |
dc.description | Oral Abstract Session - Recurrent Disease/Pathology: O-97 | - |
dc.description | Young Investigator Awards: James Fung | - |
dc.description | This free journal suppl. entitled: The ILTS 20th Annual International Congress | - |
dc.description.abstract | AIM: To determine the histological outcome after liver transplantation for patients with chronic hepatitis B (CHB) receiving oral antiviral therapy without hepatitis B immune globulin (HBIG). METHODS: All patients transplanted for CHB-related complications from January 2003 to December 2012 were included. None of the patients received HBIG. All biopsies performed 3 months after transplantation were analyzed. Biopsies were performed on the basis of graft dysfunction. Immunohistochemical study with anti-hepatitis B surface antigen (HBsAg) antibody was performed. RESULTS: A total of 440 CHB patients underwent liver transplantation with a median follow-up of 58 months (range, 0-130). Of these, 139 (31.6%) patients underwent liver biopsy for graft dysfunction, with a total of 258 biopsies performed. The median time to biopsy was 10 months (range, 3-104). Forty-five patients had positive serum HBsAg at the time of biopsy, of which 6 were positive for HBsAg stain. All 6 patients were on lamivudine with known virological rebound due to resistance. In the remaining 39 patients with negative HBsAg stain, 7 patients had grade 1 fibrosis from non-HBV related causes. Forty patients were on entecavir monotherapy, of which 9 patients were positive for serum HBsAg at the time of biopsy and all were negative for HBsAg staining; only 1 had grade 1 fibrosis from non-hepatitis B cause. In the remaining 94 patients who were HBsAg-negative at the time of biopsy, none had histological evidence of recurrence of hepatitis B. CONCLUSION: For patients without virological rebound, positive serum HBsAg was not associated with histological evidence of recurrent hepatitis B infection after liver transplantation. For patients receiving entecavir monotherapy, no histological evidence of recurrent hepatitis B was observed irrespective of the serum HBsAg status. | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jtoc/106570021 | - |
dc.relation.ispartof | Liver Transplantation | - |
dc.rights | Liver Transplantation. Copyright © John Wiley & Sons, Inc. | - |
dc.subject | Medical sciences | - |
dc.subject | Gastroenterology medical sciences | - |
dc.subject | Surgery | - |
dc.title | Histological outcome after liver transplantation for chronic hepatitis B using oral antiviral therapy alone without hepatitis B immune globulin | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Fung, J: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lo, R: loregina@hku.hk | - |
dc.identifier.email | Chan, SC: chanlsc@hkucc.hku.hk | - |
dc.identifier.email | Chok, KSH: chok6275@hku.hk | - |
dc.identifier.email | Sharr, WW: wwsharr@hku.hk | - |
dc.identifier.email | Dai, WC: daiwc@hku.hk | - |
dc.identifier.email | Cheung, TT: cheung68@hku.hk | - |
dc.identifier.email | Chan, ACY: acchan@hku.hk | - |
dc.identifier.email | Wong, T: wongtcl@hku.hk | - |
dc.identifier.email | Ng, IOL: iolng@hku.hk | - |
dc.identifier.email | Yuen, MF: mfyuen@hku.hk | - |
dc.identifier.email | Lo, CM: chungmlo@hkucc.hku.hk | - |
dc.identifier.authority | Fung, J=rp00518 | - |
dc.identifier.authority | Lo, R=rp01359 | - |
dc.identifier.authority | Chan, SC=rp01568 | - |
dc.identifier.authority | Chan, ACY=rp00310 | - |
dc.identifier.authority | Wong, T=rp01679 | - |
dc.identifier.authority | Ng, IOL=rp00335 | - |
dc.identifier.authority | Yuen, MF=rp00479 | - |
dc.identifier.authority | Lo, CM=rp00412 | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1002/lt.23901 | - |
dc.identifier.scopus | eid_2-s2.0-84932186609 | - |
dc.identifier.hkuros | 241546 | - |
dc.identifier.volume | 20 | - |
dc.identifier.issue | suppl. S1 | - |
dc.identifier.spage | S134, abstract O-97 | - |
dc.identifier.epage | S134, abstract O-97 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1527-6465 | - |